Dec 12,2022

Quibim's AI imaging solutions mark a breakthrough at RSNA

Quibim, a global leader in medical imaging analysis, consolidated its growth in the United States by closing 2022 with a 5x revenue growth due to its collaborations with radiologists, hospitals, and top-tier pharmaceutical companies. As a perfect companion, medical imaging exams, such as MRIs, CT scans, and PET scans, are performed at every single step of the disease. Quibim's innovative business model takes advantage of these standard-of-care scans offering different software solutions that deeply analyze the image and extract critical information to detect and diagnose diseases earlier.The company's goal is to accurately predict patient outcomes using data extracted from medical images to avoid unnecessary patient procedures.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 13,2022

New MRI scanner aims to deliver workflow and productivity fortitude to UK healthcare

A new MRI system designed to move patients more efficiently through the diagnostic imaging journey, from waiting-room to scan-room to home, has been introduced into the UK healthcare marketplace. The Vantage Fortian MRI scanner from Canon Medical Systems UK features innovative workflow solutions, image enhancement and accelerated scan technology, which together contribute to reducing the time required for procedures. The Vantage Fortian MRI builds on Canon Medical’s range of ‘AI-assisted’ diagnostic imaging solutions. It incorporates machine learning and deep learning technology to enhance image quality by removing noise and restoring SNR, automating many scan procedures, and confirming set-up steps to save time and reducing errors.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 13,2022

PreciseDx to Collaborate with the Champalimaud Foundation to Enhance Current Approaches of Breast Cancer Risk Assessment

PreciseDx, a leading AI company leveraging the analysis of morphology features from histology slides to provide more precise patient-specific risk information, today announced a sponsored research collaboration with the Breast Unit of the Champalimaud Clinical Center (CCC)/Champalimaud Foundation in Lisbon, Portugal. As part of the research collaboration, PreciseDx and the CCC will evaluate the performance of the PreciseDx Breast Assay in predicting breast cancer recurrence and treatment choice. The objective is to obtain clinical data and Hematoxylin and Eosin (H&E) images from a cohort of patients treated at the CCC's Breast Unit since its inception in 2011. Gaining access to these patient samples and outcomes data will allow for the development of models that are comparative to those previously produced by PreciseDx in the United States.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

Adapting to the burdens of care: a telehealth program for cancer survivors with ostomies

A prospective randomized trial comparing usual care (UC) with an Ostomy Self-Management Training (OSMT) program delivered by telehealth was conducted in patients with ostomies due to cancer. The intervention occurred over 5 weeks with survey administration at baseline, program completion, and 6 months after completion. Quantitative data were analyzed using a mixed-effects logistic model to predict mean values of resource and service use. Responses to the open-ended question were coded and analyzed with directed content analysis.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023

Ofer Sharon is the CEO of OncoHost, a biotech company in the precision oncology space. A physician by training, Sharon has leveraged his experience in pharma drug development and entrepreneurship to lead OncoHost through the development of PROphet, the company’s host response profiling platform, which will launch in the U.S. for non-small cell lung cancer (NSCLC) patients in February 2023.

PRODUCT

#platform

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

Ibex Deploys AI-powered Cancer Diagnostics Solution at UPMC

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the live deployment by the University of Pittsburgh Medical Center (UPMC) of Galen™ Prostate, an AI-based solution that supports pathologists during cancer diagnosis, at the UPMC network.

PRODUCT

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

Are Pharma Companies Ready to Harness the Promises of Real-World Data?

In recent years, real-world data (RWD) has started to show its true strength as a way to gain deeper, broader, and more actionable insight into patients and their outcomes. Buy-in from clinical trial experts, data companies, healthcare providers, and regulators like the FDA has made it easier and more attractive to start integrating RWD, and the resulting real-world evidence (RWE), into the drug development process. In partnership with Impatient Health, COTA conducted in-depth, semi-structured interviews with 20 high-level executive leaders from some of the most innovative pharma companies in the world, including Pfizer, Roche, Novartis, Sanofi, and Bristol Myers Squibb.

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

2,000 AI-Driven, Intraoperative CT-Guided Procedures Completed with LungVision™

Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today that its LungVision™ AI-driven, intraoperative CT imaging system has now been used in 2,000 diagnostic bronchoscopy procedures worldwide. Body Vision Medical's LungVision™ System uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans. This empowers bronchoscopists to biopsy from smaller, more difficult-to-access lung lesions at an earlier stage, thus maximizing the likelihood of an early diagnosis for lung cancer patients and improving

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 15,2022

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

Veracyte, Inc. today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM). The data, from a meta-analysis of 13 independent studies, show that the Afirma GSC can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules (ITNs) and that, when the test identifies a nodule as suspicious, the patient’s risk of malignancy is consistent with, and higher than, that reported in the test’s original clinical validation (CV) study.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Dec 15,2022

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that its majority-owned digital health subsidiary Veris Health Inc., has commercially launched its Veris Cancer Care Platform™. Veris executed its first commercial contract with New Jersey Cancer Care, PA, a leading oncology practice and member of the prestigious Quality Cancer Care Alliance. Veris CCP is a digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Cancer patients enrolled in the Veris CCP program receive a VerisBox™ with Veris-branded Bluetooth enabled connected health care devices.

PRODUCT

#telehealth

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY